My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Birinapant (TL32711)
    Birinapant (TL32711)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0051
    CAS #: 1260251-31-7Purity ≥98%

    Description: Birinapant (TL32711; TL-32711; TL 32711) is a novel and potent bivalent peptidomimetic of SMAC (second mitochondrial-derived activator of caspases) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins. It has potential anticancer activity. Birinapant is a SMAC mimetic antagonist, mostly to cIAP1 with a Kd of <1 nM in a cell-free assay, and is less potent to XIAP. 

    References: Breast Cancer Res Treat. 2013 Jan;137(2):359-71.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)806.94
    FormulaC42H56F2N8O6
    CAS No.1260251-31-7
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 100 mg/mL (123.9 mM)
    Water:<1 mg/mL (slightly soluble or insoluble)
    Ethanol: 55 mg/mL (68.1 mM)
    Solubility (In vivo)15% Captisol: 15mg/mL
    SynonymTL32711; TL-32711; TL 32711; SMAC mimetic; Birinapant
    Chemical Name(2S,2'S)-N,N'-((2S,2'S)-((3S,3'S,5R,5'R)-5,5'-((6,6'-difluoro-1H,1'H-[2,2'-biindole]-3,3'-diyl)bis(methylene))bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-2,1-diyl))bis(2-(methylamino)propanamide)


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In VitroBirinapant binds with XIAP and cIAP1 with Kd of 45 and<1 nM, respectively. Birinapant induces cell death as a single agent in TRAIL-insensitive SUM190 (ErbB2-overexpressing) cells (IC50, ~300 nM), and significantly increases potency of TRAIL-induced apoptosis in TRAIL-sensitive SUM149 (triple-negative, EGFR-activated) cells. Birinapant causes rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation. Birinapant in combination with TNF-α(1 ng/mL) inhibits the growth of human melanoma cell lines WTH202, WM793B, WM1366 and WM164 with IC50s of 1.8, 2.5, 7.9 and 9 nM, respectively.
    In VivoBirinapant (30 mg/kg) treatment significantly induces abrogation of tumor growth in melanoma xenotransplantation models 451Lu with.
    Animal modelHuman melanoma xenografts 451Lu
    Formulation & Dosage12.5% Captisol in distilled water; 30 mg/kg; i.p. 3 times per week 
    References[1] Krepler C, et al. Clin Cancer Res, 2013, 19(7), 1784-1794.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

     

    Birinapant

     

    Birinapant

    Krepler C, et al. Clin Cancer Res, 2013, 19(7), 1784-1794.
     

    Birinapant

    Krepler C, et al. Clin Cancer Res, 2013, 19(7), 1784-1794.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?